Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has provided an announcement.
EBR Systems, Inc., developer of the WiSE wireless cardiac pacing system for heart failure patients, reported its quarterly cash flow for the period ended 31 December 2025, showing continued investment in research and development as it began enrolment in a post-approval study and increased spending on product development. The company also lifted advertising and marketing costs to support commercialization, while administration and corporate expenses rose largely due to prepayment of annual directors’ and officers’ insurance premiums, moves that indicate a ramp-up in commercial activity despite ongoing operating cash outflows.
The cash flow report shows higher operating outlays offset by positive net cash from investing and earlier equity financing, leaving EBR Systems with US$8.4 million in cash and cash equivalents at period end. This financial positioning suggests the company is consciously deploying capital to advance clinical evidence and market penetration for its WiSE technology, with implications for its growth trajectory and the risk-reward balance faced by investors as commercialization progresses.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
EBR Systems, Inc. is a Silicon Valley-based medical device company focused on treating cardiac rhythm disease through its proprietary Wireless Stimulation Endocardially (WiSE) technology. The company’s lead product is the world’s only wireless, endocardial left ventricular pacing system for heart failure patients needing Cardiac Resynchronisation Therapy, with future applications targeted at bradycardia and other non-cardiac indications.
Average Trading Volume: 484,651
Technical Sentiment Signal: Sell
Current Market Cap: A$314.9M
Learn more about EBR stock on TipRanks’ Stock Analysis page.